Amitriptyline

Limits on what this shows

• Key negative/null findings: The Sahin 2023 dose (75 mg/kg in rats) is a toxicological, overdose-modeling dose, not a therapeutic-equivalent exposure; nicorandil's failure to reverse oxidative-stress parameters despite preventing electrical/apoptotic damage indicates the mitochondrial and oxidative pathways are not fully the same mechanism.
• At-risk subgroups: For the cardiac mitochondrial data: overdose/toxic-ingestion scenarios specifically, not standard therapeutic dosing. For the coenzyme Q10 data: the psychiatric patient population described in that study.
• Counter-evidence on record: No study was identified showing normal or unaffected mitochondrial parameters at therapeutic amitriptyline exposure; absence of such a study is itself noted as a search limitation, not as confirming evidence.

Regulatory status

Not addressed in the FDA label.

Population evidence

Moreno-Fernandez 2012 (PMID 22118833) and Bautista-Ferrufino 2011 (PMID 21501668), detailed under Coenzyme Q10 above - coenzyme Q10 is an obligate electron-transport-chain (Complex I/III) cofactor, so a documented deficiency is a direct mitochondrial-function finding, not only a nutrient-level finding. Separately: Sahin et al., "Effect of the selective mitochondrial KATP channel opener nicorandil on the QT prolongation and myocardial damage induced by amitriptyline in rats," J Pharm Pharmacol 2022/2023;75(3):415-426, PMID 36527252 - rats given amitriptyline 75 mg/kg (a toxic, supratherapeutic dose used to model overdose cardiotoxicity) showed QT/QRS prolongation, increased oxidative stress, and increased apoptosis; the mitochondrial KATP channel opener nicorandil prevented the electrical and apoptotic effects through a named mitochondrial mechanism, though it did not reverse the oxidative-stress parameters.

Mechanism

Two distinct but overlapping routes: (1) coenzyme Q10 depletion impairing electron-transport-chain function generally; (2) at toxic/overdose concentrations, disruption of cardiac mitochondrial KATP channel function contributing to apoptosis and electrical instability in heart tissue.

Counter-evidence held on record

The cardiac-mitochondrial data were generated at an overdose-modeling dose in rats and must never be presented as a standard-dose clinical effect. This entry and Coenzyme Q10 above share a common evidentiary core; see the Overlap map.

Limits on what this shows

• Key negative/null findings: The 2023 zebrafish study (PMID 37245408) combined amitriptyline with microplastic co-exposure, which is a real confound: the oxidative-stress and dysbiosis findings in that specific study cannot be cleanly attributed to amitriptyline alone, and this is flagged rather than treated as clean single-agent evidence.
• At-risk subgroups: Cannot be specified precisely without full access to the human study's population description.
• Counter-evidence on record: Only one of the four sources cited here is Tier A (human); the remainder are Tier B animal/aquatic-toxicology models, and one of those four (the microplastics co-exposure study) carries a confounding second exposure. This bounds the entry to orange rather than red.

Regulatory status

Not addressed in the FDA label.

Population evidence

Moreno-Fernandez 2012 (PMID 22118833, Tier A, human) measured oxidative-stress markers alongside coenzyme Q10 in amitriptyline-treated psychiatric patients (full effect sizes inaccessible, see Coenzyme Q10 entry). Bautista-Ferrufino 2011 (PMID 21501668, Tier B, mouse) found oxidative damage in lung and liver. Sahin 2023 (PMID 36527252, Tier B, rat, toxic dose) found increased oxidative stress in cardiac tissue. Shi Y, Chen C, Wu X, et al., "Exposure to amitriptyline induces persistent gut damages and dysbiosis of the gut microbiota in zebrafish (Danio rerio)," Comp Biochem Physiol C Toxicol Pharmacol 2022, PMID 35872240 (Tier B, zebrafish, amitriptyline alone) and Shi Y, Chen C, Han Z, et al., "Combined exposure to microplastics and amitriptyline caused intestinal damage, oxidative stress and gut microbiota dysbiosis in zebrafish," Aquat Toxicol 2023, PMID 37245408 (Tier B, zebrafish, co-exposure with microplastics - a confound, see Counter-evidence) both report intestinal oxidative-stress markers.

Mechanism

Coenzyme Q10 depletion (see above) is one named mechanistic route to oxidative stress, since reduced coenzyme Q10 impairs the electron-transport chain's capacity to manage reactive oxygen species; the toxic-dose cardiac and zebrafish-intestinal findings are consistent with this general direction across tissues and species, though the precise mechanism was not independently confirmed for each study given access limitations.

Counter-evidence held on record

This entry shares its Tier A/Tier B core evidence with Coenzyme Q10 and Mitochondrial burden above; see the Overlap map before presenting these as three independent confirmations.

Limits on what this shows

• Key negative/null findings: None identified; the search for this category returned only this one drug-specific hit plus unrelated results (an analytical-chemistry paper using copper(II) as a reagent to assay amitriptyline in vitro, and cytotoxicity assay methodology papers with no biological copper-status content).
• At-risk subgroups: Cannot be specified without access to the full study.
• Counter-evidence on record: None identified.

Regulatory status

Not addressed in the FDA label.

Population evidence

Xu H, Richardson JS, Li XM, "Dose-Related Effects of Chronic Antidepressants on Neuroprotective Proteins BDNF, Bcl-2 and Cu/Zn-SOD in Rat Hippocampus," Neuropsychopharmacology 2003;28(1):53-62, DOI 10.1038/sj.npp.1300009, PMID 12496940 (Tier B, rat) - confirmed via OpenAlex concept indexing to have tested amitriptyline specifically (among the "chronic antidepressants" compared) and to have measured Cu/Zn-SOD activity in hippocampal tissue in a dose-related manner. Neither the abstract nor full text was accessible during this review (Crossref and OpenAlex both returned bibliographic metadata only, with no abstract text; Europe PMC and Semantic Scholar were rate-limited for the remainder of the session after this query), so the direction of the Cu/Zn-SOD change (increased vs. decreased) cannot be stated here.

Mechanism

Cu/Zn-SOD is a copper- and zinc-dependent antioxidant enzyme; a change in its activity is a real functional marker of copper-dependent enzyme function, satisfying the protocol's requirement (Hard Rule 3) that a claim rest on a functional marker shown to move, not an unfalsifiable "normal blood, depleted tissue" claim. Because the direction is unconfirmed, this is graded as plausibility, not as an established depletion or excess finding.

Counter-evidence held on record

This entry must not be presented as either "amitriptyline depletes copper" or "amitriptyline protects copper-dependent enzymes" - the direction of the underlying finding is genuinely unconfirmed in this review, and a future revision should re-check this specific study with fresh tooling access before the framing is sharpened.

Limits on what this shows

• Why no grade: Both conditions for ungraded are met. A PubMed search-listing query for "amitriptyline iron" returned only incidental co-occurrences with no biological iron interaction: a toxicology review discussing intravenous lipid emulsion and hemodialysis as amitriptyline-overdose treatments (unrelated to iron), an akathisia review mentioning iron's possible role in akathisia pathophysiology generally (not tied to amitriptyline's effect on iron), an anorexia-nervosa treatment review that lists amitriptyline and iron supplementation as two separate, unrelated interventions in the same care plan, and an unrelated case report on iron-deficiency anemia presenting with oral burning. No study measuring iron status, ferritin, transferrin saturation, or iron absorption in amitriptyline-treated patients or animals was identified. No absorption-interference, chelation, or renal-wasting mechanism connecting amitriptyline to iron is documented in the FDA label or in any source located.

Tooling disclosure

This category was checked through two channels: a PubMed search-listing query (successful, returned a clean, readable zero-relevance result set rather than an error or CAPTCHA) and a follow-up PubMed query combining "amitriptyline," "ferritin," "iron deficiency," and "anemia" (blocked by proxy rate-limiting, HTTP 429). Because the first channel returned genuine, readable, non-overlapping results rather than an error, this is assessed as a real literature gap rather than a pure tooling failure, though the second, more targeted query could not be independently confirmed and should be re-run in a future revision. General open web search was unavailable for this entire review (session search budget exhausted before this dossier began), so a fringe consumer claim circulating outside PubMed/Crossref cannot be fully ruled out.

Limits on what this shows

• Key negative/null findings: Ninomiya 2022 found no change in salivary flow rate, arguing against simple dry-mouth-driven bacterial washout as the sole mechanism in the oral compartment. No human study was identified in either direction.
• At-risk subgroups: Cannot be specified for humans without clinical data; all evidence is preclinical.
• Counter-evidence on record: This is capped at yellow specifically because Tier A (human) evidence is absent, per Step 7 of the governing protocol, despite the unusually strong and consistent Tier B animal evidence across three groups and two species.

Regulatory status

Not addressed in the FDA label.

Population evidence

Zhang W, Qu W, Wang H, Yan H, "Antidepressants fluoxetine and amitriptyline induce alterations in intestinal microbiota and gut microbiome function in rats exposed to chronic unpredictable mild stress," Transl Psychiatry 2021, PMID 33602895 (Tier B, rat) - six-week treatment with both drugs reduced the Firmicutes/Bacteroidetes ratio (more Bacteroidetes, less Firmicutes); amitriptyline specifically and uniquely increased Bacteroidaceae abundance (fluoxetine did not), and both drugs altered carbohydrate-metabolism and membrane-transport pathways and antibiotic-resistance-gene profiles. Ninomiya K, Paudel D, Uehara O, et al., "Effect of Systemic Administration of Amitriptyline on Oral Microbes in Rats," In Vivo 2022;36(5):2134-2142, PMID 36099099 (Tier B, rat) - two weeks of intraperitoneal amitriptyline reduced Corynebacterium, Rothia, and Porphyromonas in oral swabs, changed beta diversity, and elevated antimicrobial peptide expression in buccal tissue, with no change in salivary flow rate. Shi Y et al., "Exposure to amitriptyline induces persistent gut damages and dysbiosis of the gut microbiota in zebrafish (Danio rerio)," Comp Biochem Physiol C Toxicol Pharmacol 2022, PMID 35872240 (Tier B, zebrafish, amitriptyline alone, no co-exposure confound) - a third independent group, third species, consistent dysbiosis direction.

Mechanism

Not fully established; amitriptyline's strong anticholinergic activity (reduced GI motility, documented on the label as constipation and rare paralytic ileus) is a plausible contributor to altered luminal transit time and bacterial composition, and its antimicrobial-peptide-inducing effect in oral tissue (Ninomiya 2022) suggests a direct host-microbe interaction independent of motility.

Counter-evidence held on record

Do not present this as "amitriptyline damages your gut microbiome" as an established human fact; it is a consistent, multi-study, drug-specific animal finding without human confirmation. It is also not a nutrient-intake claim and does not support a supplement recommendation on its own.

Limits on what this shows

• Key negative/null findings: The zero-result PubMed search is itself the relevant null finding for this specific endpoint.
• At-risk subgroups: Cannot be specified; no direct human or animal ATP data exists for this drug.
• Counter-evidence on record: None identified; the entry is explicitly labeled as extrapolation rather than direct evidence.

Regulatory status

Not addressed in the FDA label.

Population evidence

A PubMed search-listing query combining "amitriptyline," "ATP," "production," and "mitochondria" returned a confirmed clean zero-result count ("meta-log_resultcount: 0," processed without automatic term mapping) rather than a blocked or errored page, so this is treated as a genuine literature gap for direct ATP measurement. The mechanistic basis instead comes from Moreno-Fernandez 2012 (PMID 22118833, Tier A, human) and Bautista-Ferrufino 2011 (PMID 21501668, Tier B, mouse), both detailed under Coenzyme Q10 above, since coenzyme Q10 is a required cofactor for Complex I/III electron transfer that ultimately drives ATP synthase.

Mechanism

Indirect: coenzyme Q10 depletion would be expected to reduce electron-transport-chain throughput and therefore ATP synthesis capacity, but this study did not measure ATP directly, so the link is mechanistic inference, not direct observation.

Counter-evidence held on record

This entry shares its entire evidentiary basis with Coenzyme Q10 and Mitochondrial burden above and adds no independent data of its own; see the Overlap map. Do not present this as a separately confirmed finding.

Limits on what this shows

• Key negative/null findings: The FDA label's absence of any listed anemia adverse reaction is itself a relevant null finding for standard therapeutic use.
• At-risk subgroups: None established; this finding describes an in vitro blood-storage application, not a risk or benefit for amitriptyline-treated patients' own red cells.
• Counter-evidence on record: This is not a clinical finding in treated patients and must not be generalized to one; it is included because it is the only drug-specific data located for this mandatory category, and because it is protective rather than depleting, it argues against an oxygen-delivery deficiency narrative for this drug.

Regulatory status

Label hematologic adverse reactions are limited to "bone marrow depression including agranulocytosis, leukopenia, thrombocytopenia; purpura; eosinophilia" - white-cell and platelet-lineage effects. Anemia is not listed, and this absence is recorded here as a genuine null finding, not silently omitted.

Population evidence

Hoehn RS et al., "Acid Sphingomyelinase Inhibition Prevents Hemolysis During Erythrocyte Storage," Cell Physiol Biochem 2016;39(1):331-340, PMID 27352097 (Tier B, in vitro human/mouse erythrocyte storage model) - amitriptyline, used here as an acid sphingomyelinase inhibitor rather than as a psychiatric treatment, reduced free hemoglobin release (hemolysis) in a dose-dependent manner and preserved erythrocyte membrane-integrity markers during simulated blood-bank storage; transfusion of treated cells was associated with lower circulating free hemoglobin in the recipient model.

Mechanism

Acid sphingomyelinase inhibition, a pharmacologic property amitriptyline is known to have (it is a functional inhibitor of acid sphingomyelinase, independent of its serotonin/norepinephrine reuptake activity), reduces red-cell membrane sphingolipid-driven damage during storage. This is a protective, not depleting, effect on red-cell integrity, and it was studied as a storage/transfusion-science application, not as a description of amitriptyline's effect on a treated patient's own blood.

Counter-evidence held on record

This is an in vitro blood-banking finding, not evidence that amitriptyline improves a treated patient's own oxygen-carrying capacity. It must never be presented as a reason to take or continue amitriptyline for blood health.